Structure-Based Inhibitor Discovery of Class I Histone Deacetylases (HDACs)

Abstract excerpt

Class I histone deacetylases (HDACs) are promising targets for epigenetic therapies for a range of diseases such as cancers, inflammations, infections and neurological diseases. Although six HDAC inhibitors are now licensed for clinical treatments, they are all pan-inhibitors with little or no HDAC isoform selectivity, exhibiting undesirable side effects. A major issue with the currently available HDAC inhibitors...

Topics

Join the communities discussing this publication.

• Histone Deacetylase Inhibitors Research
• Peptidase Inhibition and Analysis
• Protein Degradation and Inhibitors